Endocrinology and Metabolic Disorders

EC grants marketing authorisation for Takeda’s Ninlaro capsules The European Commission (EC) has granted conditional marketing authorisation for Takeda Pharmaceutical’s Ninlaro capsules. The oral proteasome inhibitor is indicated in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma who have previously received at least one therapy. The EC’s decision was based on data from the pivotal Phase III Tourmaline-MM1 trial, which showed that the capsule with lenalidomide and dexamethasone increased the length of progression-free survival by about 40% in patients with relapsed and refractory multiple myeloma. Pfizer cuts €400M plant expans...